Shorts

In a conversation with CancerNetwork®, Adam D. Cohen, MD, spoke about the expanding role of CELMoDs as a novel therapeutic class in the treatment of patients with multiple myeloma.

1:07

CELMoDs Have “a Lot of Potential” in Multiple Myeloma Treatment Landscape

3 months ago

Adam D. Cohen, MD

María Teresa Bourlon, MD, MS, FASCO, discussed why secondary overall survival trends cannot be definitively interpreted following the early closure of the phase 2 RADICAL/Alliance A031801 trial.

0:55

Interpreting Secondary End Points After Early Futility Closure in RCC

3 months ago

María T. Bourlon, MD, MSc, FASCO

María Teresa Bourlon, MD, MS, FASCO, stressed that because pembrolizumab monotherapy already offers proven OS benefits, clinicians must weigh the higher potential toxicity of novel combination regimens against patient well-being.

1:21

Adjuvant RCC Standard of Care: OS and QOL Both Needed to Move the Needle

3 months ago

María T. Bourlon, MD, MSc, FASCO

1:39

Could a Pill One Day Prevent KRAS-Driven Cancers Before They Start?

3 months ago

Frank McCormick, PhD, FRS, DSc (Hon)

At the 2026 National ICE-T Conferences in Orlando, program director Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, spoke with CancerNetwork® about challenges surrounding payer coverage and reimbursement for CAR T-cell therapy and bispecific antibodies, detailing what she hopes payers could better understand about the treatment process.

0:47

Breaking Down Payer Misconceptions Surrounding Cellular Therapy

3 months ago

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

1:50

Why was KRAS Considered “Undruggable” for so Long?

3 months ago

Frank McCormick, PhD, FRS, DSc (Hon)

Herbert Lepor, MD, highlighted a critical issue in precision medicine: standard molecular tests often yield discordant results, and altering a treatment plan doesn’t automatically mean improving patient outcomes.

1:28

Are Prostate Cancer Molecular Signatures Driving the Right Decisions?

3 months ago

Herbert Lepor, MD

When presented with validated long-term outcome data, most men with intermediate-risk prostate cancer favor a focal approach over radical intervention, according to Herbert Lepor, MD.

0:58

Seven-Year Data Drive Patient Preference for Focal Prostate Cancer Therapy

3 months ago

Herbert Lepor, MD

At the 2026 National ICE-T Conference, program director Megan Melody, MD, MS, spoke with CancerNetwork® about how access to novel cellular therapies was a common theme across different sessions dedicated to multiple myeloma, leukemia, lymphoma, and other disease types.

0:42

Can CAR T-Cell Therapy Work in Community Oncology Settings?

3 months ago

Kirollos Hanna, PharmD, BCPS, BCOP, addressed optimal treatment strategies for patients with muscle invasive bladder cancer who experienced disease progression within 1 year of treatment with neoadjuvant pembrolizumab/enfortumab vedotin and cystectomy.

1:28

Where Does ctDNA Testing Fit Into the Recurrent MIBC Landscape?

3 months ago

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC

In a conversation with CancerNetwork® at the 2026 National ICE-T Conference, Benjamin Diamond, MD, discussed the circumstances in which bispecific antibodies could best serve as a bridging therapy to CAR T-cell therapy or as definitive therapy alone among those with multiple myeloma.

0:48

Using Bispecific Antibodies as Definitive Therapy in Multiple Myeloma

3 months ago

Benjamin Diamond, MD

Kirollos Hanna, PharmD, BCPS, BCOP, broke down the correlation between ctDNA positivity and event-free survival in muscle-invasive bladder cancer.

1:30

Who Should Receive Adjuvant Immunotherapy After a Radical Cystectomy?

3 months ago

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC

1:19

The Reality of Biopsy Needle Conservation Requests

3 months ago

Harriet Borofsky, MD

1:15

How the Brevera Recall Triggered a Supply Chain Cascade

3 months ago

Harriet Borofsky, MD

Sivraj Muralikrishnan, MD, highlighted findings from the RASolute 302 study evaluating daraxonrasib as a potential new benchmark for patients with RAS-mutated pancreatic cancer.

1:10

Practice-Changing Data in Metastatic PDAC: A New Second-Line Standard?

3 months ago

Sivraj Muralikrishnan, MD

0:55

What Does LIBRETTO-432 Mean for Precision Oncology in RET+ NSCLC?

3 months ago

Sivraj Muralikrishnan, MD

In this video, Benoit Tessoulin, MD, PhD, hematologist at Centre Hospitalier Universitaire de Nantes, Nantes, France, discussed the potential of combining epcoritamab plus lenalidomide and rituximab for patients with follicular lymphoma experiencing a relapse after first-line chemoimmunotherapy.

0:41

How the EPCORE FL-1 Regimen is Changing the Follicular Lymphoma Landscape

4 months ago

Benoit Tessoulin, MD, PhD

In a conversation with CancerNetwork® at the opening of the Melchiorre Cancer Center at Cooperman Barnabas Medical Center, a new cancer facility from RWJBarnabas Health and Rutgers Cancer Institute, Steven K. Libutti, MD, FACS, highlighted how the center will facilitate seamless multidisciplinary collaboration to enhance patient care.

1:00

Designing a New Cancer Center to Facilitate Seamless Teamwork

4 months ago

Steven K. Libutti, MD

Guilherme Perini, MD, PhD, explained how dual checkpoint inhibition serves as a proof of concept for reversing immunotherapy resistance while preserving quality of life in heavily pretreated classic Hodgkin lymphoma.

1:08

Prioritizing Response Durability in Heavily Pretreated Hodgkin Lymphoma

4 months ago

Guilherme Fleury Perini, MD, PhD

Chinmay Jani, MD, joined CancerNetwork® in the studio to discuss ongoing work dedicated to overcoming immunotherapy resistance and harnessing novel biomarkers to elevate the quality of care for patients with lung cancer.

0:34

Can Lung Cancer Become a Chronic Disease?

4 months ago

Chinmay Jani, MD

0:35

Building a “Layer of Ethics” Into Oncologic AI Tools

4 months ago

Chinmay Jani, MD

Matthew Matasar, MD, noted that while the frontMIND regimen has caught everyone’s attention, the lack of a statistically significant overall survival benefit means treating oncologists must carefully balance efficacy against incremental adverse effects and scheduling burdens.

0:49

Weighing the frontMIND PFS Benefit Vs Toxicity in High-Risk DLBCL

4 months ago

Matthew J. Matasar, MD

Eric Miller, MD, discussed clinical thresholds that may prompt the adoption of a bladder-sparing approach among patients with urothelial carcinoma.

1:01

Patient Values Inform Treatment Decision-Making in Urothelial Carcinoma

4 months ago

Eric Miller, MD

0:51

Exploring the Weight Loss Potential of GLP-1 Agonists in Patients With Breast Cancer

4 months ago

Sherry Shen, MD

1:22

How GLP-1 Agonists Improve Overall Survival in Breast Cancer Care

4 months ago

Sherry Shen, MD

Yan Leyfman, MD, broke down a review article titled “Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma”, which was published in the journal ONCOLOGY in May 2026.

0:58

Investigating the Evolution of Cellular Therapy in Multiple Myeloma

4 months ago

Yan Leyfman, MD

Bachy noted that the initiation of the phase 3 MorningLyte trial (NCT06284122) was directly inspired by the phase 1b results, expressing that the same mosunetuzumab regimen was being compared against conventional chemoimmunotherapy.

0:57

Phase 1 Mosunetuzumab Data Inspires Phase 3 MorningLyte Study

4 months ago

1:03

How is CAR T-Cell Therapy Transforming Expectations in Multiple Myeloma?

4 months ago

Yan Leyfman, MD

1:11

How a Nurse Builds Deep Trust with Patients

4 months ago

Kassiane Saieed, DNP, AGNP-C

In a conversation with CancerNetwork® at the European Hematology Association (EHA) 2026 Congress, Matthew S. Davids, MD, MMSc, discussed what updated findings from the phase 3 BRUIN CLL-322 trial (NCT04965493) represent for the clinical utility of pirtobrutinib (Jaypirca) plus venetoclax (Venclexta) and rituximab (Rituxan; PVR) for patients with previously treated chronic lymphocytic leukemia.

Shorts

Trending on CancerNetwork

Meaning-Centered Therapy, Psychiatry Referrals, and Humanistic Cancer Care

How Psycho-Oncology Addresses Existential Distress, Body Image, and Intimacy

How to Work With a Patient Who Declines Cancer Treatment

Targeting Cyclin E1, KRAS, and DNA Repair Beyond PARP in Ovarian Cancer

Screening for Depression and Starting Antidepressants in Oncology Care